Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Report Date: March 20, 2015
Event: The Company entered into an Exchange Agreement with Tang Capital Partners, LP (TCP) to exchange 2,000 shares of Series A Convertible Preferred Stock for 2,000 shares of Series A-1 Convertible Preferred Stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It reports a specific balance sheet adjustment resulting from the stock exchange:
- Face Value Adjustment: Decrease of $2 million in the face value of Series A Preferred Stock.
- Equity Impact: Corresponding increase of $2 million in the face value of Series A-1 Preferred Stock, resulting in a $2 million addition to stockholders' equity.
- Reporting Date for Balance Sheet: March 31, 2015.
Material Changes
The primary material change is the modification of the terms of the Series A Preferred Stock held by TCP. The new Series A-1 Preferred Stock terms are identical to the original Series A Preferred Stock, except for the elimination of cash penalties that would have been due if the Company failed to have enough Common Stock available for conversion.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the exchange was executed to eliminate potential cash penalties related to conversion availability.
Regulatory Status: The issuance of Series A-1 Preferred Stock was not registered under the Securities Act of 1933. It was exempt under Section 3(a)(9) as an exchange with an existing security holder.
Compensation: No commission or remuneration was paid for soliciting the exchange.
Outlook: The filing text does not provide forward-looking guidance, risk factors, or contingencies beyond the specific transaction details.
Investor Verification Checklist
- Verify the exact terms of the Series A-1 Convertible Preferred Stock to confirm the elimination of cash penalties.
- Confirm the impact of the $2 million equity adjustment on the Company's balance sheet as of March 31, 2015.
- Review the Company's current Common Stock availability to assess future conversion risks.
- Check subsequent filings for any further modifications to preferred stock terms or liquidity events.